**1. Introduction**

Since it was first identified in 2003, bisphosphonate-induced osteonecrosis has been under growing control by medical and dental specialist alike because it affects cancer patients re‐ ceiving intra-venous bisphosphonate therapy and osteoporosis patients receiving oral bi‐ sphosphonate therapy.

It is of significant importance to introduce the mechanism of action of this type of medica‐ tions, way of distribution and risk of complication during or after treatment with them. A strategy of preparation, medication support and techniques before, during and after dental surgery procedures and especially placement of dental implants must be clarified in order to avoid bisphosphonate-induced osteonecrosis.
